Mobile website
Archive > Volume 26 Issue 9 > 2019,26(9):941-947. DOI:10.3872/j.issn.1007-385X.2019.09.002 Prev Next
Expert Forum
Research progress on the application of LAG-3 and its inhibitors in cancer immunotherapy
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
[Abstract] Lymphocyte-activation gene 3 (LAG-3), also known as CD223, is a 498-amino-acid type I transmembrane protein encoded by LAG-3 gene, which consists of extracellular, transmembrane and intracellular regions.LAG-3 negatively regulates T lymphocyte by binding extracellular domain to ligand, thus avoiding autoimmunitycaused by T cell over-activation. Like programmed cell death 1 (PD-1) and cytotoxic T lymphocyte antigen 4 (CTLA-4), LAG-3 is an important immune checkpoint in vivo and plays a balanced regulatory role in human immune system.Tumor cells escape the surveillance of the immune system by over-expressing LAG-3 ligand. With the development in research of immune checkpoints, LAG-3 has become a new generation of immunotherapy targets after PD-1 and CTLA-4. This article reviews the structure and function of LAG-3 and the application of its inhibitors in tumor immunotherapy, in order to provide reference for the further study of LAG-3.
Keywords:
Project Supported:
Project supported by the National Natural Science Foundation of China (No. 31470897, 81602457), and the Naval General Hospital Innovation and Cultivation Fund (No.CXPY201817)
Clc Number:
